Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
BMC Urology|July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinationsYasser Ged, Ruby Gupta, Cihan Duzgol, et al.
Cancer Immunology Research|August 20, 2016
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk GroupsGuillermo de Velasco, Diana Miao, Martin H Voss, et al.
European Urology|November 7, 2022
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy CombinationsKelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, et al.
The Journal of Urology|May 11, 2023
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive NephrectomyStephen W Reese, Sari Khaleel, Andrew Silagy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
The Journal of Urology|July 7, 2023
Reply by AuthorsStephen W Reese, Sari Khaleel, Andrew Silagy, et al.
Clinical Genitourinary Cancer|December 1, 2024
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical TrialsSahil D Doshi, Andrea Knezevic, Carlene Gonzalez, et al.
Clinical Genitourinary Cancer|June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 23, 2020
An evaluation of the role of tumor load in cytoreductive nephrectomyAndrew W Silagy, Cihan Duzgol, Julian Marcon, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
BMC Urology|July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinationsYasser Ged, Ruby Gupta, Cihan Duzgol, et al.
Cancer Immunology Research|August 20, 2016
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk GroupsGuillermo de Velasco, Diana Miao, Martin H Voss, et al.
European Urology|November 7, 2022
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy CombinationsKelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, et al.
The Journal of Urology|May 11, 2023
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive NephrectomyStephen W Reese, Sari Khaleel, Andrew Silagy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
The Journal of Urology|July 7, 2023
Reply by AuthorsStephen W Reese, Sari Khaleel, Andrew Silagy, et al.
Clinical Genitourinary Cancer|December 1, 2024
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical TrialsSahil D Doshi, Andrea Knezevic, Carlene Gonzalez, et al.
Clinical Genitourinary Cancer|June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 23, 2020
An evaluation of the role of tumor load in cytoreductive nephrectomyAndrew W Silagy, Cihan Duzgol, Julian Marcon, et al.
Pageof 15